Merck & Co., Inc. (NYSE:MRK) is among the Most Profitable Healthcare Stocks to Buy. On January 21, TheFly reported that BofA analysts included Merck & Co., Inc. (NYSE:MRK) on their “US 1 List,” which includes the company’s top investment ideas.
A day earlier, Bernstein reiterated his Market Perform rating on Merck & Co., Inc. (NYSE:MRK), with an unchanged price target of $95. While analyzing obstacles related to the company’s growth prospects this year, the company raised the question of whether significant growth beyond Keytruda could only emerge in 2027.
One billion photos/Shutterstock.com
Additionally, Bernstein highlighted the company’s renewed focus on mergers and acquisitions, noting its “willingness to spend tens of billions” on potential strategic deals. Despite this, the company is “struggling to validate whether there is a path to building confidence” in Merck & Co., Inc.’s (NYSE:MRK) near-term growth momentum. Thus, its analysis indicates a performance in line with the general market.
Overall, Merck & Co., Inc. (NYSE:MRK) has mixed analyst sentiment, with just over half of analysts recommending a Buy and the remaining 45% maintaining a cautious view. With a 1-year average consensus price target of $120, the stock has an upside potential of 10.93%.
Merck & Co., Inc. (NYSE:MRK) is a New Jersey-based healthcare company that develops and manufactures human health pharmaceutical products for a variety of areas. Founded in 1891, the company is committed to saving and improving lives through the power of science.
While we recognize MRK’s potential as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: The best and worst Dow stocks for the next 12 months and 10 unstoppable stocks that could double your money.
Disclosure: None.